Cargando…

Targeting DORIS Remission and LLDAS in SLE: A Review

Remission is the established therapeutic goal for patients with systemic lupus erythematosus (SLE) and is currently defined by the widely adopted Definition Of Remission In SLE (DORIS) criteria. Attainment of remission is rare in the clinical setting, thus an alternative, pragmatic treatment target...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parra Sánchez, Agner R., van Vollenhoven, Ronald F., Morand, Eric F., Bruce, Ian N., Kandane-Rathnayake, Rangi, Weiss, Gudrun, Tummala, Raj, Al-Mossawi, Hussein, Sorrentino, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654283/ https://www.ncbi.nlm.nih.gov/pubmed/37798595 http://dx.doi.org/10.1007/s40744-023-00601-w

Ejemplares similares

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

LLDAS is an attainable treat-to-target goal in childhood-onset SLE
por: Wahadat, Mohamed Javad, et al.
Publicado: (2021)

Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study
por: Golder, Vera, et al.
Publicado: (2017)

Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study
por: Louthrenoo, Worawit, et al.
Publicado: (2020)

Correction: 2021 DORIS definition of remission in SLE: final recommendations from an international task force
Publicado: (2022)

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
por: Morand, Eric F, et al.
Publicado: (2018)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus
por: Godsell, Jack, et al.
Publicado: (2016)

Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2019)

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2020)

Clinical associations of cognitive dysfunction in systemic lupus erythematosus
por: Raghunath, Sudha, et al.
Publicado: (2023)

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis
por: Northcott, Melissa, et al.
Publicado: (2022)

Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus
por: Vincent, Fabien B, et al.
Publicado: (2018)

Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus
por: Raghunath, Sudha, et al.
Publicado: (2022)

Analysis of serum interleukin(IL)‐1α, IL‐1β and IL‐18 in patients with systemic sclerosis
por: Lin, Emily, et al.
Publicado: (2019)

Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus
por: Mende, Rachel, et al.
Publicado: (2018)

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021)

Analysis of serum macrophage migration inhibitory factor and D‐dopachrome tautomerase in systemic sclerosis
por: Vincent, Fabien B, et al.
Publicado: (2018)

DESY: At DORIS
Publicado: (1975)

Doris Salcedo /
por: Salcedo, Doris, 1958-
Publicado: (2000)

Dori Caymmi
por: Caymmi, Dori, 1943-
Publicado: (1988)

String of successful trials in SLE: have we cracked the code?
por: van Vollenhoven, Ronald
Publicado: (2020)

What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
por: Furie, Richard, et al.
Publicado: (2021)

Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus
por: Connelly, K. L., et al.
Publicado: (2016)

DESY: Experiments at DORIS
Publicado: (1975)

DESY: Dedication of DORIS
Publicado: (1974)

DESY: The upsilon at DORIS
Publicado: (1978)

DESY: Wiggling at DORIS
Publicado: (1984)

DESY: DORIS at 16
Publicado: (1989)

DESY: DORIS-III
Publicado: (1991)

DESY : DORIS III
Publicado: (1991)

Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Persistent expression of autoantibodies in SLE patients in remission
por: Yurasov, Sergey, et al.
Publicado: (2006)

The association between diet and glucocorticoid treatment in patients with SLE
por: Lourdudoss, Cecilia, et al.
Publicado: (2016)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus
por: Connelly, K. L., et al.
Publicado: (2018)

DESY: Particles stored in DORIS
Publicado: (1974)

DESY: Experiments start in DORIS
Publicado: (1974)

DESY: Results from DORIS
Publicado: (1977)

Cannot write session to /tmp/vufind_sessions/sess_n9mfsg88o4s7uinbrfavr17lpe